Inventor · disambiguated record
Nathan Higginson-Scott
Also filed as: HIGGINSON-SCOTT NATHAN
22 granted patents·26 pending applications·124 citations·filing 2015–2025
94Inventor score
Files withPANDION OPERATIONS INC22SEISMIC THERAPEUTIC INC10PANDION THERAPEUTICS INC8PFIZER5GAO HULIAN1
Top patents by PatentIndex Score
48 records- 0197US10676516B2Targeted immunotolerancePANDION THERAPEUTICS INC·Filed 2018·Granted Jun 9, 2020·26 cites·29 claims
- 0297US10174091B1IL-2 muteinsPANDION THERAPEUTICS INC·Filed 2018·Granted Jan 8, 2019·31 cites·25 claims
- 0397US10174092B1IL-2 muteinsPANDION THERAPEUTICS INC·Filed 2018·Granted Jan 8, 2019·28 cites·25 claims
- 0494US11091527B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2019·Granted Aug 17, 2021·5 cites·2 claims
- 0593US11091526B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2019·Granted Aug 17, 2021·4 cites·2 claims
- 0693US10946068B2IL-2 muteins and uses thereofPANDION THERAPEUTICS INC·Filed 2018·Granted Mar 16, 2021·9 cites·27 claims
- 0791US11466068B2Targeted immunotolerancePANDION OPERATIONS INC·Filed 2020·Granted Oct 11, 2022·2 cites·11 claims
- 0891US10961310B2Targeted immunotolerancePANDION OPERATIONS INC·Filed 2018·Granted Mar 30, 2021·6 cites·7 claims
- 0991US10392438B2Bispecific antibodiesPFIZER·Filed 2015·Granted Aug 27, 2019·9 cites·24 claims
- 1089US2024239858A1Il-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2024·Application pending·0 cites
- 1189US2024247039A1Il-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2024·Application pending·0 cites
- 1286US12030945B2Variant IgG Fc polypeptides and uses thereofSEISMIC THERAPEUTIC INC·Filed 2023·Granted Jul 9, 2024·1 cites·30 claims
- 1381US10633649B1Methods for profiling extracellular vesicles from combinatorial phage display librariesVERILY LIFE SCIENCES LLC·Filed 2017·Granted Apr 28, 2020·2 cites·7 claims
- 1480US11965008B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2021·Granted Apr 23, 2024·0 cites·19 claims
- 1579US11945852B2IL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2021·Granted Apr 2, 2024·0 cites·22 claims
- 1677US11981715B2Tissue targeted immunotolerance with a CD39 effectorPANDION OPERATIONS INC·Filed 2021·Granted May 14, 2024·1 cites·7 claims
- 1776US12129499B2Protease variants and uses thereofSEISMIC THERAPEUTIC INC·Filed 2024·Granted Oct 29, 2024·0 cites·25 claims
- 1874US12091694B2Fc fusion molecules and uses thereofSEISMIC THERAPEUTIC INC·Filed 2023·Granted Sep 17, 2024·0 cites·16 claims
- 1974US2019169255A1Il-2 muteins and uses thereofPANDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2070US2025027068A1Protease variants and uses thereofSEISMIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 2170US2025002582A1Targeted immunotolerance with a pd-1 agonistPANDION OPERATIONS INC·Filed 2024·Application pending·0 cites
- 2270US2019169254A1Il-2 muteins and uses thereofPANDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2369USRE50550EIL-2 muteins and uses thereofPANDION OPERATIONS INC·Filed 2022·Granted Aug 26, 2025·0 cites·27 claims
- 2469US2025074984A1VARIANT IgG FC POLYPEPTIDES AND USES THEREOFSEISMIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 2568US2024025995A1Dual targeted immune regulating compositionsSEISMIC THERAPEUTIC INC·Filed 2023·Application pending·0 cites
- 2667US2024409911A1Fc fusion molecules and uses thereofSEISMIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 2766US2023272072A1Dual targeted immune regulating compositionsSEISMIC THERAPEUTIC INC·Filed 2022·Application pending·0 cites
- 2863US11970524B2Recombinant ROBO2 proteins, compositions, methods and uses thereofPFIZER·Filed 2020·Granted Apr 30, 2024·0 cites·25 claims
- 2962US11779632B2IL-2 muteins and uses thereofPANDION OPERATION INC·Filed 2021·Granted Oct 10, 2023·0 cites·20 claims
- 3062US2022002409A1Targeted ImmunotolerancePANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 3160US2024368283A1Molecules for modulating the immune system and uses thereofSEISMIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 3259US10906955B2Recombinant ROBO2 proteins, compositions, methods and uses thereofPFIZER·Filed 2018·Granted Feb 2, 2021·0 cites·48 claims
- 3358US2024228619A9Pancreas targeted therapeutics and uses thereofPANDION OPERATIONS INC·Filed 2022·Application pending·0 cites
- 3457US2025320292A1Kidney-glomerular targeted immunotherapyPANDION OPERATIONS INC·Filed 2022·Application pending·0 cites
- 3557US2020123260A1Bispecific antibodiesPFIZER·Filed 2019·Application pending·0 cites
- 3657US2025019431A1Kidney targeted immunotolerancePANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 3754US2021206856A1Targeted immunotolerance with a pd-1 agonistPANDION THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3853US2024376225A1Cd21 antibodies and uses thereofGAO HULIAN·Filed 2022·Application pending·0 cites
- 3952US2024301064A1Pd-1 antibodies, polypeptides and uses thereofPANDION OPERATIONS INC·Filed 2022·Application pending·0 cites
- 4051US2024010722A1Madcam targeted therapeutics and uses thereofPANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 4151US2024262905A1Skin targeted immunotolerancePANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 4251US2024052034A1Multi-paratopic anti-pd-1 antibodies and uses thereofPANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 4349US2022041713A1Targeted immunotolerancePANDION OPERATIONS INC·Filed 2019·Application pending·0 cites
- 4447US2023235004A1Tissue targeted immunotolerance with pd-1 agonists or il-2 muteinsPANDION OPERATIONS INC·Filed 2021·Application pending·0 cites
- 4546US11739146B2MAdCAM targeted immunotolerancePANDION OPERATIONS INC·Filed 2020·Granted Aug 29, 2023·0 cites·9 claims
- 4645US2021277085A1Targeted immunotolerancePANDION THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4744US11365253B2Anti-ROBO2 antibodies, compositions, methods and uses thereofPFIZER·Filed 2018·Granted Jun 21, 2022·0 cites·22 claims
- 4843US2025340857A1IgE PROTEASES AND USES THEREOFSEISMIC THERAPEUTIC INC·Filed 2025·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →